Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $165.96 USD
Change Today +0.18 / 0.11%
Volume 1.6M
UTHR On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Paul A. Mahon J.D.

Executive Vice President of Strategic Planning, General Counsel and Corporate Secretary, United Therapeutics Corporation
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2014


Mr. Paul A. Mahon, J.D. has been an Executive Vice President of Strategic Planning at United Therapeutics Corporation since November 2003 and has also been as its General Counsel and Corporate Secretary since 1996. Mr. Mahon serves as an Executive Vice President and General Counsel of Lung Rx, Inc. He served as a Senior Vice President of United Therapeutics Corporation since June 2001. He served at United Therapeutics Corporation in his capacity as principal and managing ...

Read Full Background

Corporate Headquarters*

1040 Spring Street
Silver Spring, Maryland 20910

United States

Phone: 301-608-9292
Fax: 301-608-9291

Board Members Memberships*

There is no Board Members Memberships data available.


There is no Education data available.

Other Affiliations*

Annual Compensation*

Total Annual Compensation$730,988

Stock Options*

All Other Compensation$16,400
Exercised Options122,750
Exercised Options Value$9,543,330
Exercisable Options437,625
Exercisable Options Value$34,512,806
Unexercisable Options280,625
Unexercisable Options Value$15,620,456
Total Value of Options$59,676,592
Total Number of Options841,000

Total Compensation*

Total Annual Cash Compensation$1,202,051
Total Short Term Compensation$730,988
Other Long Term Compensation$16,400
Total Calculated Compensation$6,648,029
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTHR:US $165.96 USD +0.18


Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
Jean-Paul Clozel M.D.Founder, Chief Executive Officer and Director
Actelion Ltd.
David L. Hallal Chief Executive Officer and Director
Alexion Pharmaceuticals, Inc.
Mark C. Rohr Chairman of the Board, Chief Executive Officer and President
Celanese Corporation
Shigenobu Maekawa President and Representative Director
Nippon Shinyaku Co. Ltd.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at